This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To report headache (HA) data collected from subjects in a longitudinal study of human immunodeficiency virus (HIV)-1 and the central nervous system (CNS). Design/methods: Baseline data from 229 ambulatory HIV-seropositive (HIV+) and 53 seronegative control subjects were analyzed. Subjects were classified by the presence or absence of HIV-1-associated HAs and HIV-1-associated systemic and neurologic disease. Subjects were followed longitudinally for up to 5 years. Results: In the cross-sectional analysis, significant associations were observed between HIV-1-associated HAs and (1) anxiety and depression, and (2) a history of drug use, psychiatric disease, and non-HIV-1 neurologic disease. No significant differences in laboratory values were found between subjects with HIV-1-associated HA compared with those without HA. When HIV+ subjects were followed longitudinally, onset of new HIV-1-associated systemic or neurologic disease over 1 year was not predicted by the presence of an HIV-1-associated HA at baseline. Conclusion: Headaches are common in HIV+ persons at all stages of disease. Presence of HIV-1-associated HAs at baseline were not associated with neurologic disease progression over 1 year of follow-up in our sample.
NEUROLOGY 1996;47: 487-494
- Copyright 1996 by Advanstar Communications Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Alert Me
Recommended articles
Pediatric migraine and the International Headache Society (IHS) criteria
Characterization of chronic daily headaches in children in a multidisciplinary headache center
Biomarkers of HIV-1 CNS infection and injury
Mechanism of Action of Intravenous Immunoglobulin and Therapeutic Considerations in the Treatment of Autoimmune Neurologic Diseases